Stock AnalizAbbott Laboratories ABT
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Abbott Laboratories (ABT) is a healthcare company listed in the US with a market value of about $188.0B. In the twelve months to September 30, 2026 it had revenue of $48.2B and net income of $4.7B, a net margin of 9.7%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is shareholder returns (4/5); the weakest is value (0/5).
Key numbers: a P/E of 40.3, a price to free cash flow of 27.8, 5-year revenue growth of 5% a year, a 5-year average ROIC of 11%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 20% below the current price.
Score: 1.8 / 5
Checks passed
- Strong R&D investment or growth above 20%
- Profitable 5 years in a row
- Positive free cash flow
- Interest covered more than 5 times
- Liabilities below 60% of assets
- Pays a dividend
- 20% to 100% of free cash flow returned to shareholders
- Dividend 3 years in a row
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.2B | $44.3B | $42.0B | $40.1B | $43.7B | $43.1B | $34.6B | $31.9B | $30.6B | $27.4B | $20.9B |
| Net income | $4.7B | $6.5B | $13.4B | $5.7B | $6.9B | $7.1B | $4.5B | $3.7B | $2.4B | $477M | $1.4B |
| Free cash flow | $6.8B | $7.4B | $6.4B | $5.1B | $7.8B | $8.6B | $5.7B | $4.5B | $4.9B | $4.4B | $2.1B |
| EPS (diluted) | $2.69 | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 | $2.50 | $2.06 | $1.33 | $0.27 | $0.94 |
| Net margin | 9.7% | 14.7% | 31.9% | 14.3% | 15.9% | 16.4% | 13.0% | 11.6% | 7.7% | 1.7% | 6.7% |
| ROIC | — | 9.4% | 8.6% | 10.2% | 12.8% | 13.2% | 9.2% | 8.2% | 5.9% | 2.1% | 5.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 26 analysts is $118.91, 10% above the current price; targets range from $100.00 to $130.00; the consensus rating is “Buy”; expected EPS is $5.52 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Abbott Laboratories’s P/E ratio?
About 40.3, based on the last twelve months of diluted earnings per share (forward P/E about 18.6).
Is Abbott Laboratories stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 20% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Abbott Laboratories pay a dividend?
Yes. The dividend yield is about 2.31%, and it has paid dividends for 10 years in our data.
Is Abbott Laboratories a good stock to buy?
We do not give buy or sell advice. Abbott Laboratories scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.